In search of rigorous data on how to palliate the EGFR inhibitor-induced rash.

Abstract

Epidermal growth factor receptor (EGFR) inhibitors have emerged as important drugs in cancer therapy, providing a proven survival advantage for some patients with non–small-cell lung cancer, colorectal cancer, head and neck cancer, and pancreas cancer.[1,2] Now for the bad news: In over 50% of patients, this class of agents results in a conspicuous and… (More)

Topics

  • Presentations referencing similar topics